Skip to main content
SpringerLink
Log in

Apoptotic action of estrogen

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

Estrogen as a mitogen stimulates cell proliferation and prevents cell death in many cell types. In patients, estrogen is known to stimulate breast and uterus cancer development. Ironically, high doses of estrogen can induce regression of hormone-dependent breast cancer in postmenopausal women. The comprehensive mechanism by which estrogen induces tumor recession in breast cancer is still unknown, but activation of the Fas/FasL pathways plays a key role in this process. Laboratory studies show that the apoptotic action of estrogen is the major factor leading to cell number decreases in several cell types. The effects of estrogen are estrogen-receptor dependent. In this mini review, we will focus on the latest findings regarding estrogen apoptotic effects in several cell models, including breast cancer cells, and summarize the possible mechanisms involved in these estrogen mediated processes. New potential implications for the pharmacological control of breast cancer with estrogen in post-menopausal women are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cooke PS, Buchanan DL, Lubahn DB, Cunha GR. Mechanism of estrogen action: Lessons from the estrogen receptor-alpha knockout mouse. Biol Reprod 1998; 59: 470–475.

    Google Scholar 

  2. Thompson EB. Apoptosis and steroid hormones. Mol Endocrinol 1994; 8: 665–673.

    Google Scholar 

  3. Song RX, McPherson RA, Adam L, et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 2002; 16: 116–127.

    Google Scholar 

  4. Sun M, Paciga JE, Feldman RI, et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 2001; 61: 5985–5991.

    Google Scholar 

  5. Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000; 11: 99–110.

    Google Scholar 

  6. Budtz PE. Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. Cell Prolif 1999; 32: 289–302.

    Google Scholar 

  7. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation 1997; 95: 1505–1514.

    Google Scholar 

  8. Cameron DA, Ritchie AA, Miller WR. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. Eur J Cancer 2001; 37: 1545–1553.

    Google Scholar 

  9. Gelmann EP. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog? Journal of the National Cancer Institute 1996; 88: 224–226.

    Google Scholar 

  10. Song RXD, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17{beta}-estradiol. Journal of the National Cancer Institute 2001; 93: 1714–1723.

    Google Scholar 

  11. Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. Journal of the National Cancer Institute 1996; 88: 908–917.

    Google Scholar 

  12. Nilsen J, Mor G, Naftolin F. Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol 2000; 43: 64–78.

    Google Scholar 

  13. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997; 186: 489–495.

    Google Scholar 

  14. Okasha SA, Ryu S, Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology 2001; 163: 49–62.

    Google Scholar 

  15. Lee Y, Renaud RA, Friedrich TC, Gorski J. Estrogen causes cell death of estrogen receptor stably transfected cells via apoptosis. J Steroid Biochem Mol Biol 1998; 67: 327–332.

    Google Scholar 

  16. Levenson AS, Jordan VC. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J Steroid Biochem Mol Biol 1994; 51: 229–239.

    Google Scholar 

  17. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462.

    Google Scholar 

  18. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445–1449.

    Google Scholar 

  19. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–257.

    Google Scholar 

  20. Talapatra S, Thompson CB. Growth factor signaling in cell survival: Implications for cancer treatment. J Pharmacol Exp Ther 2001; 298: 873–878.

    Google Scholar 

  21. Chinnaiyan AM, O'Rourke K, Yu GL, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 1996; 274: 990–992.

    Google Scholar 

  22. Guan B, Yue P, Lotan R, Sun SY. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene 2002; 21: 3121–3129.

    Google Scholar 

  23. Chao W, Shen Y, Li L, Rosenzweig A. Importance of FADD signaling in serum-deprivation-and hypoxia-induced cardiomyocyte apoptosis. J Biol Chem 2002.

  24. Morgan M, Thorburn J, Pandolfi PP, Thorburn A. Nuclear and cytoplasmic shuttling of TRADD induces apoptosis via different mechanisms. J Cell Biol 2002; 157: 975–984.

    Google Scholar 

  25. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000; 74: 281–286.

    Google Scholar 

  26. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405–413.

    Google Scholar 

  27. Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 1999; 4: 153–164.

    Google Scholar 

  28. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285–291.

    Google Scholar 

  29. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996; 87: 619–628.

    Google Scholar 

  30. Pastorino JG, Tafani M, Farber JL. Tumor necrosis factor induces phosphorylation and translocation of BAD through a phosphatidylinositide-3-OH kinase-dependent pathway. J Biol Chem 1999; 274: 19411–19416.

    Google Scholar 

  31. Santen RJ, Worgul TJ, Samojlik E, et al. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New England Journal of Medicine 1981; 305: 545–551.

    Google Scholar 

  32. Kennedy BJ. Massive estrogen administration in premenopausal women with breast cancer. Cancer 1962; 15: 641–648.

    Google Scholar 

  33. Carter AC, Sedransk N, Kelley RM, et al. Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. Journal of the American Medical Association 1977; 237: 2079–2085.

    Google Scholar 

  34. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment 2001; 67: 111–116.

    Google Scholar 

  35. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Research and Treatment 1999; 54: 117–122.

    Google Scholar 

  36. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Rubin J, Frytak S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. New England Journal of Medicine 1981; 304: 16–21.

    Google Scholar 

  37. Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396–405.

    Google Scholar 

  38. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000; 6: 2028–2036.

    Google Scholar 

  39. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995; 80: 2918–2925.

    Google Scholar 

  40. Yue W, Santen RJ, Wang JP, Hamilton CJ, Demers LM. Aromatase within the breast. Endocr Relat Cancer 1999; 6: 157–164.

    Google Scholar 

  41. Sonnenschein C, Szelei J, Nye TL, Soto AM. Control of cell proliferation of human breast MCF7 cells: Serum and estrogen resistant variants. Oncol Res 1994; 6: 373–381.

    Google Scholar 

  42. Soto AM, Sonnenschein C. The two faces of janus: Sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst 2001; 93: 1673–1675.

    Google Scholar 

  43. Mor G, Kohen F, Garcia-Velasco J, et al. Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 2000; 73: 185–194.

    Google Scholar 

  44. Kelly MJ, Lagrange AH, Wagner EJ, Ronnekleiv OK. Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways. Steroids 1999; 64: 64–75.

    Google Scholar 

  45. Santen R, Jeng MH, Wang JP, et al. Adaptive hypersensitivity to estradiol: Potential mechanism for secondary hormonal responses in breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology 2001; 79: 115–125.

    Google Scholar 

  46. Dong L, Wang W, Wang F, et al. Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999; 274: 32099–32107.

    Google Scholar 

  47. Jeng MH, Shupnik MA, Bender TP, et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998; 139: 4164–4174.

    Google Scholar 

  48. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 2000; 62: 167–175.

    Google Scholar 

  49. Chen Q, Hung FC, Fromm L, Overbeek PA. Induction of cell cycle entry and cell death in postmitotic lens fiber cells by overexpression of E2F1 or E2F2. Invest Ophthalmol Vis Sci 2000; 41: 4223–4231.

    Google Scholar 

  50. Cobb MH. MAP kinase pathways. Prog Biophys Mol Biol 1999; 71: 479–500.

    Google Scholar 

  51. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18: 2967–2987.

    Google Scholar 

  52. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20: 147–155.

    Google Scholar 

  53. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281: 1317–1322.

    Google Scholar 

  54. Bissonnette RP, McGahon A, Mahboubi A, Green DR. Functional Myc-Max heterodimer is required for activation-induced apoptosis in T cell hybridomas. J Exp Med 1994; 180: 2413–2418.

    Google Scholar 

  55. Green DR. A Myc-induced apoptosis pathway surfaces. Science 1997; 278: 1246–1247.

    Google Scholar 

  56. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI. Requirement for the CD95 receptor-ligand pathway in c-Mycinduced apoptosis. Science 1997; 278: 1305–1309.

    Google Scholar 

  57. EL-Ashry D, Miller DA, Kharbanda S, Lippman ME, Kern FG. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 1997; 15: 423–435.

    Google Scholar 

  58. Takei H, Yao K, Jordan VC. Estrogen-induced apoptosis in a tamoxifen stimulated MCF-7 tumor model [abstract]. Breast Cancer Research and Treatment 1998; 50(3):252.

    Google Scholar 

  59. Zhang CC, Shapiro DJ. Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 2000; 275: 479–486.

    Google Scholar 

  60. Jenkins JK, Suwannaroj S, Elbourne KB, Ndebele K, McMurray RW. 17-beta-estradiol alters Jurkat lymphocyte cell cycling and induces apoptosis through suppression of Bcl-2 and cyclin A. Int Immunopharmacol 2001; 1: 1897–1911.

    Google Scholar 

  61. Szelei J, Soto AM, Geck P, et al. Identification of human estrogen-inducible transcripts that potentially mediate the apoptotic response in breast cancer. J Steroid Biochem Mol Biol 2000; 72: 89–102.

    Google Scholar 

  62. Joly-Pharaboz M, Ruffion A, Roch A, et al. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 2000; 73: 237–249.

    Google Scholar 

  63. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002; 4: 133–136.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, VA, 22901, USA

    R. X.-D. Song & R. J. Santen

Authors
  1. R. X.-D. Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. J. Santen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. X.-D. Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Song, R.XD., Santen, R.J. Apoptotic action of estrogen. Apoptosis 8, 55–60 (2003). https://doi.org/10.1023/A:1021649019025

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021649019025

Search

Navigation